Epicardial adipose tissue in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis and trial sequential analysis

作者全名："Lan, Yi; Ma, Qianli; Luo, Guangming; Yang, Heping; Li, Yingrui; Zhang, Qiao"

作者地址："[Lan, Yi; Ma, Qianli; Luo, Guangming; Yang, Heping; Zhang, Qiao] Songshan Hosp, Dept Pneumol, Chongqing, Peoples R China; [Li, Yingrui] Chongqing Med Univ, Affiliated Hosp 2, Dept Cardiol, Chongqing, Peoples R China"

通信作者："Zhang, Q (通讯作者)，Songshan Hosp, Dept Pneumol, Chongqing, Peoples R China.; Li, YR (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Cardiol, Chongqing, Peoples R China."

来源：BMC PULMONARY MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001022892500002

JCR分区：Q2

影响因子：2.6

年份：2023

卷号：23

期号：1

开始页：　

结束页：　

文献类型：Review

关键词：Epicardial adipose tissue; Chronic obstructive pulmonary disease; Meta-analysis

摘要："BackgroundLimited data suggest that chronic obstructive pulmonary disease (COPD) patients have pathologic elevated epicardial adipose tissue (EAT), which is splanchnic fat tissue with anti-inflammatory properties and regulating free fatty acids functions. Therefore, there is a need for meta-analysis to explore the relationship between EAT and COPD.MethodsOnline databases were systematically searched for studies about EAT in COPD patients published up to October 5th, 2022. The EAT data of the COPD patient group and the control group were included. Trial sequential analysis (TSA) and meta-analysis were applied to assess the difference in EAT between patients with and without COPD. TSA software and Stata 12.0 were used in all statistical analyses.ResultsThe final analysis included 5 studies (n = 596 patients). COPD patients had significantly more EAT than control subjects (SMD: 0.0.802; 95% CI: 0.231, 1.372; P = 0.006; TSA-adjusted 95% CI 1.20, 1.80; P < 0.0001). And higher CRP levels in COPD patients than non-COPD patients, whereas triglycerides and LDL were not significantly different between patients with and without COPD.ConclusionEAT is abnormally elevated in COPD patients, which may be related to systemic inflammatory responses in COPD.PROSPERO numberCRD42021228273."

基金机构：　

基金资助正文：